Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 19/20 | 0.59 |
| ▸ | LOXL2 | Q9Y4K0 | 6/20 | 0.59 |
| ▸ | MAOA | P21397 | 4/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23391726 | 0.83 | CA2 (0.47) | LOXLOXL2MAOACA2 | |
| Hydrochloric Acid SCHEMBL10341115 | 0.82 | CA2 (0.46) | LOXLOXL2MAOACA2 | |
| SCHEMBL3131218 | 0.81 | LOX (0.86) | LOXLOXL2MAOAMAOB | |
| SCHEMBL2010210 | 0.81 | CA2 (0.56) | LOXLOXL2MAOACA2 | |
| SCHEMBL7893099 | 0.81 | LOX (0.58) | LOXLOXL2MAOAMAOB | |
| SCHEMBL38666703 | 0.81 | CA2 (0.47) | LOXLOXL2MAOAMAOBCA2 | |
| SCHEMBL4648549 | 0.81 | CA2 (0.47) | LOXLOXL2MAOACA2 | |
| Hydrochloric Acid SCHEMBL15486681 | 0.79 | LOX (0.83) | LOXLOXL2MAOAMAOB | |
| SCHEMBL10340905 | 0.78 | CA2 (0.58) | LOXLOXL2MAOACA2 | |
| SCHEMBL4645445 | 0.78 | CA2 (0.44) | LOXLOXL2MAOACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115151550-B | External nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) modulators and uses thereof | 桑福德·伯纳姆·普雷比医学发现研究所 | 2024-11-22 | — | — | CN | disclosed |
| US-11654203-B2 | Dual-targeted carbonic anhydrase ix complex and contrast agent thereof | Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R.O.C (TW) | 2023-05-23 | — | — | US | disclosed |
| US-20230121698-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2023-04-20 | — | — | US | disclosed |
| EP-4081528-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-115151550-A | Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) modulators and uses thereof | 桑福德·伯纳姆·普雷比医学发现研究所 | 2022-10-04 | — | — | CN | disclosed |
| WO-2021133915-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021133915-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-07-01 | — | — | WO | disclosed |
| US-20210154334-A1 | DUAL-TARGETED CARBONIC ANHYDRASE IX COMPLEX AND CONTRAST AGENT THEREOF | Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R.O.C (TW) | 2021-05-27 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | HOCHGURTEL MATTHIAS | 2008-09-11 | — | — | US | disclosed |
| US-20080207607-A1 | Heterotricyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080207607-A1 | Heterotricyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121698-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | ENPP1, ENPP3, PPA1 | LOX 1752/4885LOXL2 3263/4885MAOA 1382/4885 |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | LOX 1178/4885LOXL2 1949/4885MAOA 337/4885 |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | LOX 1171/4885LOXL2 1779/4885MAOA 381/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | LOX 1178/4885LOXL2 1949/4885MAOA 337/4885 |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | MMP12, MMP13, MMP25 | LOX 162/4885LOXL2 895/4885MAOA 137/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | LOX 1178/4885LOXL2 1949/4885MAOA 337/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | LOX 1178/4885LOXL2 1949/4885MAOA 337/4885 |
| US-20080207607-A1 | Heterotricyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | LOX 927/4885LOXL2 1594/4885MAOA 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.